Edesa Biotech (EDSA) has released an update.
Edesa Biotech, a clinical-stage biopharmaceutical company, is set to participate in key dermatology meetings in early March 2024, showcasing their advancements in treating immuno-inflammatory diseases. The company’s leading drug candidate, EB05, is currently in a Phase 3 study for Acute Respiratory Distress Syndrome, while other innovative treatments for diseases like vitiligo and Allergic Contact Dermatitis are also in development. Stakeholders can schedule meetings with Edesa by reaching out via the company’s email during the upcoming conferences.
For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.
